Latest Hotspot

EMA Reviews Application for PADCEV® Plus KEYTRUDA® Combo as Initial Therapy for Progressive Bladder Cancer

2 February 2024
3 min read

On January 26, Pfizer Inc. together with Astellas Pharma Inc. reported that the European Medicines Agency has officially accepted to assess a Type II variation application concerning the joint use of PADCEV® (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab). This application is for the proposed use as an initial therapy for adult individuals who have not yet been treated for locally advanced or metastatic urothelial carcinoma.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Upon authorization, the combination of PADCEV and KEYTRUDA could revolutionize current treatment approaches by providing a first-of-its-kind option that doesn't rely on chemotherapies based on platinum, which are traditionally used as the initial standard therapy for la/mUC.

Worldwide, each year sees the emergence of roughly 573,000 new cases of bladder cancer and a consequent 212,000 fatalities. Europe alone witnesses the diagnosis of bladder cancer in around 200,000 individuals annually.

"For individuals in Europe dealing with advanced bladder cancer, the survival rates are notably low, necessitating the introduction of groundbreaking treatments that prolong life. This milestone moves us one step closer towards fulfilling our goal: to provide transformative solutions that tackle the pressing needs of patients and revolutionize the current state of care for advanced urothelial cancer," stated Roger Dansey, M.D., Senior Vice President and the Head of Oncology Development at Pfizer.

The EMA’s Human Medicines Committee and following that, the European Commission, are anticipated to issue their evaluative feedback and final rulings pertaining to the submitted Type II variation application within the 2024 calendar year. Previously, in December 2023, the U.S. Food and Drug Administration granted approval for the use of this combination therapy.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of January 31, 2024, there are 4 investigational drugs for the Tubulin and nectin-4 target, including 26 indications, 16 R&D institutions involved, with related clinical trials reaching 55, and as many as 141 patents.

PADCEV (enfortumab vedotin) is a first-in-class antibody-drug conjugate that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer. Enfortumab Vedotin represents a significant advancement in the field of biomedicine, offering a promising treatment option for various neoplasms and urogenital diseases. Its approval in the United States and ongoing regulatory processes in China indicate its potential to make a positive impact on patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Unlock the Power of Synapse: A Guide to Searching Hydrochlorothiazide
Drug Insights
2 min read
Unlock the Power of Synapse: A Guide to Searching Hydrochlorothiazide
2 February 2024
Hydrochlorothiazide, a small molecule drug, targets the NCC co-transporter as an inhibitor, exhibiting an assortment of therapeutic effects.
Read →
KEYTRUDA® Boosts DFS in High-Risk Urothelial Carcinoma Post-Surgery
Latest Hotspot
3 min read
KEYTRUDA® Boosts DFS in High-Risk Urothelial Carcinoma Post-Surgery
2 February 2024
KEYTRUDA® (Pembrolizumab) Enhances Disease-Free Survival (DFS) as Adjuvant in High-Risk Urothelial Carcinoma Post-Surgery.
Read →
How to Effectively Search for Tizanidine on Synapse
Drug Insights
2 min read
How to Effectively Search for Tizanidine on Synapse
2 February 2024
Tizanidine Hydrochloride, a minuscule molecule drug, is a potent agonist that targets the ADRA2 receptor with high specificity.
Read →
Dupixent® Gets FDA Approval for Eosinophilic Esophagitis Treatment in Pediatric Patients
Latest Hotspot
3 min read
Dupixent® Gets FDA Approval for Eosinophilic Esophagitis Treatment in Pediatric Patients
2 February 2024
Dupixent® has been granted FDA approval as the exclusive therapy indicated for pediatric patients over the age of 1 diagnosed with eosinophilic esophagitis (EoE).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.